Renal complications of mitomycin C therapy with special reference to the total dose.
One hundred forty-two patients with gastrointestinal cancer were treated with combination chemotherapy containing mitomycin C. The mitomycin C dose was less than or equal to 15 mg/m2 every 53rd day and the total cumulative dose was between 25 and 250 mg. Ten of the evaluable 118 patients (8.5%) developed renal toxicity due to mitomycin C. Five of these ten patients had microangiopathic hemolytic anemia, too. Six of them died 2 to 4.5 months after the last mitomycin C dose and four are alive 14 to 30 months after the last dose. Only 1 of the 63 patients (1.6%) who received less than 50 mg/m2 mitomycin C developed renal toxicity. Four of the 37 patients (10.8%) who received 50 to 69 mg/m2 and 5 of 18 (27.8%) who received more than 70 mg/m2 of mitomycin C developed nephrotoxicity. The toxicity of mitomycin C seems to be dose related, the safe total dose being less than 50 mg/m2 if delivered in doses of 10 to 15 mg/m2 at 8-week intervals.
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects*; D011507:Proteinuria / Q000139:chemically induced
D008937:Mitomycins; D016685:Mitomycin; D003404:Creatinine